Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.

Hindupur SV, Schmid SC, Koch JA, Youssef A, Baur EM, Wang D, Horn T, Slotta-Huspenina J, Gschwend JE, Holm PS, Nawroth R.

Int J Mol Sci. 2020 Feb 7;21(3). pii: E1106. doi: 10.3390/ijms21031106.

2.

Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).

Schmid SC, Koll FJ, Rödel C, Maisch P, Sauter A, Beckert F, Seitz A, Kübler H, Flentje M, Chun F, Combs SE, Schiller K, Gschwend JE, Retz M.

BMC Cancer. 2020 Jan 3;20(1):8. doi: 10.1186/s12885-019-6503-6.

3.

Impact of a Changing Population Structure and Clustering of Cancer in Prostate Cancer Patients Depending on a First-Degree Family History.

Meissner VH, Bittner R, Kron M, Schiele S, Schulwitz H, Gschwend JE, Herkommer K.

Urol Int. 2019 Dec 20:1-8. doi: 10.1159/000504789. [Epub ahead of print]

PMID:
31865349
4.

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.

Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD.

Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11.

5.

Reply by Authors.

Minervini A, Campi R, Lane BR, De Cobelli O, Sanguedolce F, Hatzichristodoulou G, Antonelli A, Noyes S, Mari A, Rodriguez-Faba O, Keeley FX, Langenhuijsen J, Musi G, Klatte T, Roscigno M, Akdogan B, Furlan M, Karakoyunlu N, Marszalek M, Capitanio U, Volpe A, Brookman-May S, Gschwend JE, Smaldone MC, Uzzo RG, Carini M, Kutikov A; SIB International Consortium.

J Urol. 2019 Nov 27:101097JU000000000000059102. doi: 10.1097/JU.0000000000000591.02. [Epub ahead of print] No abstract available.

PMID:
31774733
6.

Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.

Vogel MME, Kessel KA, Schiller K, Devecka M, Gschwend JE, Weichert W, Wilkens JJ, Combs SE.

Radiat Oncol. 2019 Nov 11;14(1):198. doi: 10.1186/s13014-019-1391-0.

7.

Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study.

Minervini A, Campi R, Lane BR, De Cobelli O, Sanguedolce F, Hatzichristodoulou G, Antonelli A, Noyes S, Mari A, Rodriguez-Faba O, Keeley FX, Langenhuijsen J, Musi G, Klatte T, Roscigno M, Akdogan B, Furlan M, Karakoyunlu N, Marszalek M, Capitanio U, Volpe A, Brookman-May S, Gschwend JE, Smaldone MC, Uzzo RG, Carini M, Kutikov A; SIB International Consortium.

J Urol. 2019 Oct 14:101097JU0000000000000591. doi: 10.1097/JU.0000000000000591. [Epub ahead of print]

PMID:
31609167
8.

[What causes prostate cancer: patient-perceived causes].

Goethe VE, Dinkel A, Schulwitz H, Nöhreiter A, Gschwend JE, Herkommer K.

Aktuelle Urol. 2019 Oct 8. doi: 10.1055/a-1005-6273. [Epub ahead of print] German.

PMID:
31594005
9.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Doehn C, Gschwend JE, Kuczyk MA.

Aktuelle Urol. 2019 Sep 4. doi: 10.1055/a-0972-0914. [Epub ahead of print] German.

PMID:
31486061
10.

Extended Lymph Node Dissection for Bladder Cancer: Do Clinical Trials Rule Out a Benefit?

Heck MM, Gschwend JE.

Eur Urol Focus. 2019 Aug 19. pii: S2405-4569(19)30212-3. doi: 10.1016/j.euf.2019.08.003. [Epub ahead of print]

PMID:
31439506
11.

Advances in targeted alpha therapy for prostate cancer.

De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O; Targeted Alpha Therapy Prostate Working Group .

Ann Oncol. 2019 Nov 1;30(11):1728-1739. doi: 10.1093/annonc/mdz270.

12.

Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer.

Tong Z, Sathe A, Ebner B, Qi P, Veltkamp C, Gschwend JE, Holm PS, Nawroth R.

J Exp Clin Cancer Res. 2019 Jul 22;38(1):322. doi: 10.1186/s13046-019-1322-9.

13.

[50 years of systemic therapy of urinary bladder cancer].

Retz M, von Amsberg G, Horn T, Gschwend JE, Maisch P.

Aktuelle Urol. 2019 Aug;50(4):358-365. doi: 10.1055/a-0945-8340. Epub 2019 Jun 26. German.

PMID:
31242517
14.

Factors Associated with Low Sexual Desire in 45-Year-Old Men: Findings from the German Male Sex-Study.

Meissner VH, Schroeter L, Köhn FM, Kron M, Zitzmann M, Arsov C, Imkamp F, Hadaschik B, Gschwend JE, Herkommer K.

J Sex Med. 2019 Jul;16(7):981-991. doi: 10.1016/j.jsxm.2019.04.018. Epub 2019 Jun 10.

PMID:
31196838
15.

[Internet use after prostate cancer : Search for information and trust in disease-related information in long-term survivors].

Linden AJ, Dinkel A, Schiele S, Meissner VH, Gschwend JE, Herkommer K.

Urologe A. 2019 Sep;58(9):1039-1049. doi: 10.1007/s00120-019-0966-6. German.

PMID:
31172242
17.

Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.

Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC.

J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1. Review.

PMID:
31042108
18.

Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.

Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, Schottelius M, van Leeuwen FWB, van der Poel HG, Heck M, Gschwend JE, Weber W, Eiber M, Maurer T.

Eur Urol. 2019 Oct;76(4):517-523. doi: 10.1016/j.eururo.2019.03.045. Epub 2019 Apr 12.

PMID:
30987843
19.

The Role of Magnetic Resonance Imaging in the Diagnosis of Penile Fracture in Real-Life Emergency Settings: Comparative Analysis with Intraoperative Findings.

Sokolakis I, Schubert T, Oelschlaeger M, Krebs M, Gschwend JE, Holzapfel K, Kübler H, Gakis G, Hatzichristodoulou G.

J Urol. 2019 Sep;202(3):552-557. doi: 10.1097/JU.0000000000000211. Epub 2019 Aug 8.

PMID:
30840543
20.

Erectile Dysfunction in 45-Year-Old Heterosexual German Men and Associated Lifestyle Risk Factors and Comorbidities: Results From the German Male Sex Study.

Hallanzy J, Kron M, Goethe VE, Köhn FM, Schmautz M, Arsov C, Hadaschik B, Imkamp F, Gschwend JE, Herkommer K.

Sex Med. 2019 Mar;7(1):26-34. doi: 10.1016/j.esxm.2018.11.004. Epub 2019 Jan 9.

21.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
22.

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M.

Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22.

PMID:
30473431
23.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15.

PMID:
30337060
24.

Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men: Results From the German Male Sex-Study.

Goethe VE, Angerer H, Dinkel A, Arsov C, Hadaschik B, Imkamp F, Gschwend JE, Herkommer K.

Sex Med. 2018 Dec;6(4):282-290. doi: 10.1016/j.esxm.2018.08.001. Epub 2018 Sep 28.

25.

Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy.

Mayer M, Selig K, Tüttelmann F, Dinkel A, Gschwend JE, Herkommer K.

Fam Cancer. 2019 Apr;18(2):221-230. doi: 10.1007/s10689-018-0101-7.

PMID:
30229510
26.

Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy.

Vogel MME, Kessel KA, Gschwend JE, Weichert W, Wilkens JJ, Combs SE.

Strahlenther Onkol. 2019 Feb;195(2):131-144. doi: 10.1007/s00066-018-1359-2. Epub 2018 Sep 4.

PMID:
30182246
27.

Positron-emission tomography imaging in urological oncology: Current aspects and developments.

Rauscher I, Eiber M, Weber WA, Gschwend JE, Horn T, Maurer T.

Int J Urol. 2018 Nov;25(11):912-921. doi: 10.1111/iju.13779. Epub 2018 Aug 13. Review.

28.

[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society].

Hupe MC, Merseburger AS, de Wit M, Rexer H, Gschwend JE, Krege S.

Aktuelle Urol. 2018 Aug;49(4):346-354. doi: 10.1055/a-0645-1076. Epub 2018 Aug 7. German.

PMID:
30086593
29.

Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy.

Westenfelder KM, Lentes B, Rackerseder J, Navab N, Gschwend JE, Eiber M, Maurer T.

Clin Genitourin Cancer. 2018 Aug;16(4):245-247. doi: 10.1016/j.clgc.2018.05.009. Epub 2018 May 29. No abstract available.

PMID:
29858124
30.

One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer.

Thalgott M, Düwel C, Rauscher I, Heck MM, Haller B, Gafita A, Gschwend JE, Schwaiger M, Maurer T, Eiber M.

J Nucl Med. 2018 Dec;59(12):1850-1856. doi: 10.2967/jnumed.117.207696. Epub 2018 May 24.

31.

Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study.

Autenrieth ME, Seidl C, Bruchertseifer F, Horn T, Kurtz F, Feuerecker B, D'Alessandria C, Pfob C, Nekolla S, Apostolidis C, Mirzadeh S, Gschwend JE, Schwaiger M, Scheidhauer K, Morgenstern A.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1364-1371. doi: 10.1007/s00259-018-4003-6. Epub 2018 Apr 11.

PMID:
29644393
32.

99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.

Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.

Eur Urol. 2019 Apr;75(4):659-666. doi: 10.1016/j.eururo.2018.03.013. Epub 2018 Apr 4.

PMID:
29625755
33.

[Ketogenic diet: insufficient study results and lack of positive clinical benefits].

Maisch P, Gschwend JE, Retz M.

Urologe A. 2018 May;57(5):607-608. doi: 10.1007/s00120-018-0638-y. German. No abstract available.

PMID:
29623361
34.

[Chemotherapy-induced nausea and vomiting : Current recommendations for prophylaxis].

Storz E, Gschwend JE, Retz M.

Urologe A. 2018 May;57(5):532-542. doi: 10.1007/s00120-018-0606-6. Review. German.

PMID:
29589051
35.

[Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma].

Miller K, Gschwend JE, Merseburger A, Retz M, Stenzl A.

Aktuelle Urol. 2018 Apr;49(2):142-156. doi: 10.1055/s-0043-123067. Epub 2018 Mar 27. Review. German.

PMID:
29587321
36.

Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.

Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R.

Clin Cancer Res. 2018 May 15;24(10):2342-2349. doi: 10.1158/1078-0432.CCR-17-3771. Epub 2018 Feb 20.

37.

Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands.

Rauscher I, Horn T, Eiber M, Gschwend JE, Maurer T.

World J Urol. 2018 Apr;36(4):603-608. doi: 10.1007/s00345-018-2200-3. Epub 2018 Jan 25. Review.

PMID:
29372353
38.

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.

Eur Urol. 2018 May;73(5):656-661. doi: 10.1016/j.eururo.2018.01.006. Epub 2018 Jan 19.

PMID:
29358059
39.

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.

Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R.

PLoS One. 2018 Jan 22;13(1):e0190854. doi: 10.1371/journal.pone.0190854. eCollection 2018.

40.

[Efficacy of a ketogenic diet in urological cancers patients : A systematic review].

Maisch P, Gschwend JE, Retz M.

Urologe A. 2018 Mar;57(3):307-313. doi: 10.1007/s00120-017-0563-5. German.

PMID:
29322234
41.

Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.

Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM, Horn T, Gschwend JE, Schwaiger M, Eiber M, Maurer T.

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612. doi: 10.1007/s00259-017-3887-x. Epub 2017 Nov 28.

PMID:
29185010
42.

Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.

Thalgott M, Kron M, Brath JM, Ankerst DP, Thompson IM, Gschwend JE, Herkommer K.

World J Urol. 2018 Feb;36(2):177-185. doi: 10.1007/s00345-017-2122-5. Epub 2017 Nov 21.

PMID:
29164326
43.

[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].

Gschwend JE, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J, König F, Machtens S, Pantel K, Thomas C.

Urologe A. 2018 Jan;57(1):34-39. doi: 10.1007/s00120-017-0533-y. German.

PMID:
29071398
44.

Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.

Maurer T, Gschwend JE, Eiber M.

Curr Opin Urol. 2018 Mar;28(2):191-196. doi: 10.1097/MOU.0000000000000458. Review.

PMID:
29028767
45.

[PSMA-radioguided surgery in localised recurrent prostate cancer].

Horn T, Rauscher I, Eiber M, Gschwend JE, Maurer T.

Urologe A. 2017 Nov;56(11):1417-1423. doi: 10.1007/s00120-017-0516-z. Review. German.

PMID:
29022058
46.

The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.

Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD.

Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20.

PMID:
28939004
47.

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.

Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.

PMID:
28818355
48.

Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists.

James N, Graham J, Maurer T, Eiber M, Gschwend JE.

Am Soc Clin Oncol Educ Book. 2017;37:344-357. doi: 10.14694/EDBK_175496.

49.

Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).

Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, Eiber M, Schwaiger M, Kübler H, Gschwend JE, Combs SE.

BMC Cancer. 2017 May 22;17(1):361. doi: 10.1186/s12885-017-3341-2.

50.

Prostate cancer-related anxiety in long-term survivors after radical prostatectomy.

Meissner VH, Herkommer K, Marten-Mittag B, Gschwend JE, Dinkel A.

J Cancer Surviv. 2017 Dec;11(6):800-807. doi: 10.1007/s11764-017-0619-y. Epub 2017 May 21.

PMID:
28528448

Supplemental Content

Loading ...
Support Center